Lorazepam, a new benzodiazepine derivative, in the treatment of anxiety: a double-blind clinical evaluation
Abstract
Ninety-five adult outpatients suffering from moderate to severe anxiety were randomly assigned to treatment with lorazepam or placebo in a double-blind four-week study. Patients were evaluated at pretreatment and after two and four weeks of treatment using three rating scales. Lorazepam, at an average daily dose of 3.2 mg twice daily, was highly effective in relieving anxiety as documented by clinically and statistically significant differences over placebo in most of the items on all rating scales at all rating periods. No serious adverse effects were reported, and there were no adverse interactions with other medications, including digitalis and aspirin.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).